Agenus to Unveil Three-Year Survival Data for Ovarian Cancer Therapy at IGCS 2026
Event summary
- Agenus will present three-year overall survival data for botensilimab (BOT) + balstilimab (BAL) in recurrent ovarian cancer at IGCS 2026.
- The data comes from the recurrent ovarian cancer cohort of the Phase 1b C-800-01 study, including platinum-refractory/resistant patients.
- Presentation scheduled for October 3, 2026, in Montreal, Canada.
- Botensilimab is an Fc-enhanced anti-CTLA-4 antibody, while balstilimab is an anti-PD-1 antibody.
The big picture
Agenus' presentation at IGCS 2026 comes as immuno-oncology combinations continue to gain traction in treating refractory cancers. The focus on three-year survival data underscores the growing emphasis on long-term efficacy in oncology trials. If the results are compelling, this could bolster Agenus' position in the immuno-oncology space, particularly in ovarian cancer, where treatment options remain limited.
What we're watching
- Clinical Efficacy
- How the three-year overall survival data will position BOT+BAL against existing therapies in recurrent ovarian cancer.
- Regulatory Pathway
- Whether the data will accelerate regulatory filings or discussions for BOT+BAL in ovarian cancer.
- Market Differentiation
- The pace at which Agenus can leverage this data to differentiate BOT+BAL in a competitive immuno-oncology landscape.
Related topics